FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.
The approval is based on results from the phase 3 randomized, open-label CheckMate-67T trial, which demonstrated noninferiority for the coprimary end points of time-averaged concentration over 28 days and minimum concentration at a steady state of Opdivo Qvantig versus intravenous Opdivo. Additionally, the trial showed an overall response rate for Opdivo Qvantig of 24 percent versus 18 percent in the intravenous Opdivo arm.
"Over the last decade, Opdivo has evolved as an immunotherapy option used in many indications across tumor types," Adam Lenkowsky, executive vice president and chief commercialization officer at Bristol Myers Squibb, said in a statement. "With this new option, we look forward to further helping cancer patients with an administration method that gives them faster delivery."
Approval of subcutaneous Opdivo Qvantig was granted to Bristol Myers Squibb.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
TUESDAY, Aug. 19, 2025 -- Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study...
Autoimmune Diseases Linked to Digestive System Cancers
FRIDAY, Aug. 15, 2025 -- Autoimmune diseases are associated with certain digestive system cancers, according to a review published in the September issue of...
Adenoma Detection Rate of Standard Colonoscopy Declines After Exposure to AI-Assisted Colonoscopy
WEDNESDAY, Aug. 13, 2025 -- Exposure to artificial intelligence (AI)-assisted colonoscopy is associated with a reduction in the adenoma detection rate (ADR) by endoscopists...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.